Cite
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
MLA
Makker, Vicky, et al. “Lenvatinib plus Pembrolizumab in Patients with Advanced Endometrial Cancer: An Interim Analysis of a Multicentre, Open-Label, Single-Arm, Phase 2 Trial.” Lancet Oncology, vol. 20, no. 5, May 2019, pp. 711–18. EBSCOhost, https://doi.org/10.1016/S1470-2045(19)30020-8.
APA
Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., Schmidt, E. V., Guo, M., Sachdev, P., Shumaker, R., Aghajanian, C., & Taylor, M. (2019). Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncology, 20(5), 711–718. https://doi.org/10.1016/S1470-2045(19)30020-8
Chicago
Makker, Vicky, Drew Rasco, Nicholas J Vogelzang, Marcia S Brose, Allen L Cohn, James Mier, Christopher Di Simone, et al. 2019. “Lenvatinib plus Pembrolizumab in Patients with Advanced Endometrial Cancer: An Interim Analysis of a Multicentre, Open-Label, Single-Arm, Phase 2 Trial.” Lancet Oncology 20 (5): 711–18. doi:10.1016/S1470-2045(19)30020-8.